West Pharmaceutical Services - WST Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" West Pharmaceutical Services stock.
View analyst ratings for West Pharmaceutical Services or view top-rated stocks.

West Pharmaceutical Services' stock was trading at $469.01 at the beginning of the year. Since then, WST shares have decreased by 27.1% and is now trading at $341.70.
View the best growth stocks for 2022 here.

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our earnings forecast for West Pharmaceutical Services.

West Pharmaceutical Services, Inc. (NYSE:WST) announced its earnings results on Thursday, July, 28th. The medical instruments supplier reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.28. The medical instruments supplier earned $771.30 million during the quarter, compared to analysts' expectations of $754.25 million. West Pharmaceutical Services had a trailing twelve-month return on equity of 29.08% and a net margin of 23.41%. West Pharmaceutical Services's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 EPS.
Read West Pharmaceutical Services' conference call transcript.

West Pharmaceutical Services announced a quarterly dividend on Thursday, April 28th. Investors of record on Wednesday, July 20th will be paid a dividend of $0.18 per share on Wednesday, August 3rd. This represents a $0.72 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date is Tuesday, July 19th.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services(NYSE:WST) pays an annual dividend of $0.72 per share and currently has a dividend yield of 0.21%. West Pharmaceutical Services has been increasing its dividend for 29 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of West Pharmaceutical Services is 7.99%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 7.31% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $9.00-$9.15 for the period, compared to the consensus earnings per share estimate of $9.32. The company issued revenue guidance of $2.95 billion-$2.98 billion, compared to the consensus revenue estimate of $3.05 billion.

107 employees have rated West Pharmaceutical Services CEO Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among West Pharmaceutical Services' employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by many different retail and institutional investors. Top institutional investors include Brown Advisory Inc. (1.46%), Riverbridge Partners LLC (0.73%), ProShare Advisors LLC (0.66%), Sumitomo Mitsui Trust Holdings Inc. (0.60%), Congress Asset Management Co. MA (0.46%) and Victory Capital Management Inc. (0.41%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner, Quintin J Lai and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $341.70.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $25.30 billion and generates $2.83 billion in revenue each year. The medical instruments supplier earns $661.80 million in net income (profit) each year or $9.01 on an earnings per share basis.

West Pharmaceutical Services employs 10,065 workers across the globe.

West Pharmaceutical Services was founded in 1923.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for West Pharmaceutical Services is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.